Branden Moriarity - University of Minnesota Innovator
Branden Moriarity harnesses the power of genome engineering, where scientists reprogram DNA, to develop innovative immunotherapy approaches for treating highly lethal forms of cancer. Moriarity’s work, combined with that of his colleagues, was the foundation for B-MoGen Biotechnologies Inc., a University startup company launched in 2016. He currently serves as B-MoGen’s chief scientific officer. Moriarity, a Masonic Cancer Center researcher, was a winner of the 2019 Early Innovator Award.